Fibrocell/UCLA Study on Human Skin Cells Yields Promising Results
Fibrocell Science, Inc.(OTC: FCSC) announced today that its research collaboration with UCLA has resulted in a discovery that may lead to a more predictable, commercially viable method of producing stable, induced pluripotent stem (iPS) cells from adult skin cells. The study has been accepted for publication in the Stem Cell Research and Therapy peer-reviewed journal and the provisional paper is available online (http://stemcellres.com/content/4/1/15/abstract ). It was conducted under the guidance of James Byrne, PhD, assistant professor, UCLA Department of Molecular and Medical Pharmacology, at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.
“We continue to be pleased with the results of our collaboration with UCLA to pursue the full potential of fibroblasts,” said David Pernock, CEO and Board Chair, Fibrocell Science.
The cells may be used by academic researchers and pharmaceutical companies to evaluate new drug compounds for safety and to develop patient-specific therapies for multiple disease states, including heart disease, Parkinson’s disease and diabetes. Using skin cells is more advantageous to the patient than obtaining cells from bone marrow or adipose tissue (fat). A skin biopsy is quicker to perform, less painful and minimally invasive.
Dr. Byrne’s study found human skin cells cultured in the presence of a chemical known as BAY11 resulted in reproducible increased expression of the OCT4 gene that did not inhibit normal cell growth. OCT4 is involved in many cell processes, but is primarily known to maintain pluripotency and regulate cell differentiation. It is typically used as a marker to identify undifferentiated cells.
The development of a more stable method to create iPS cells from skin cells allows for the potential of a reproducible commercial manufacturing process. The study was performed at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and Department of Molecular and Medical Pharmacology at UCLA in conjunction with the Department of Cell Biology and Neuroscience at Rutgers University.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com .
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the final discovery of a more predictable, commercially-viable method of producing stable, induced pluripotent stem cells (iPSC) and the ability of the Company to generate any future licensing opportunities based on the foregoing. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.